A Comparative Analysis of the Results From 4 Trials of β-Blocker Therapy for Heart Failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS

Journal of Cardiac Failure

Volumn 9, Issue 5, 2003, Pages 354-363

  Domanski, Michael J ^a   Krause Steinrauf, Heidi ^a,b   Massie, Barry M ^c   Deedwania, Prakash ^b   Follmann, Dean ^a   Kovar, David ^d   Murray, David ^e   Oren, Ron ^f   Rosenberg, Yves ^a   Young, James ^g   Zile, Michael ^h   Eichhorn, Eric ⁱ  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e San Antonio Center for Clinical Research   (United States)

^f UNIVERSITY OF IOWA   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h RALPH H JOHNSON VA MEDICAL CENTER   (United States)

ⁱ VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Heart failure; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL;

AGE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; HEART DEATH; HEART FAILURE; HEART RATE; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SUDDEN DEATH; SURVIVAL; SYSTOLIC BLOOD PRESSURE;

EID: 10744230755     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/S1071-9164(03)00133-7     Document Type: Article

References (37)

1. Packer M. The neurohumoral hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Pfeffer M, Braunwald E, Moye L, Basta L, Brown E, Cuddy T, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992;327:669-77.
5. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
6. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
7. Packer M, Coats A, Fowler M, Roecker EB, Coats AJS, Katus HA, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
8. The BEST Investigators. A trial of the β-adrenergic blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
9. The BEST Steering Committee. Design of the β-blocker Evaluation of Survival Trial (BEST). Am J Cardiol 1995;75:1220-3.
10. The CIBIS-II Scientific Committee. Design of the Cardiac Bisoprolol Study II. Fundam Clin Pharmacol 1997;11:38-42.
11. The International Steering Committee for the MERIT-HF Study Group. Rationale, design and organization of the metoprolol CR/XL randomized trail in heart failure (MERIT-HF). Am J Cardiol 1997;80:54J-8J.
12. Lechat P. Personal communication. 2000.
13. Wikstrand J. Personal communication. 2000.
14. Packer M. Personal communication. 2002.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. SAS. Proprietary Software Release 6.12. Cary, NC: SAS Institute, Inc, 1996.
17. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34:187-202.
18. Matterson B, Reda D, Cushman W, Massie B, Freis E, Kochar M, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21.
19. Johnson J, Burlew B, Sitles R. Racial differences in β -adrenoreceptor-mediated responsiveness. J Cardiovasc Pharmacol 1995;25:90-6.
20. Dries D, Exner D, Gersh R, Cooper H, Carson P, Domanski M. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16.
21. Carson P, Ziesche S, Johnson G, Cohn J, for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Failure 1999;5:178-87.
22. Exner D, Dries D, Domanski M, Cohn J. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
23. Moore J, Mason D, Green S, Hsu J, Liggett S. Racial differences in the frequencies of cardiac β (1)-adrenergic receptor polymorphisms: analysis of c145A > G and c1165 G > C. Hum Mut 1999:14:271.
24. Gottlieb S. Personal communication. January 2000.
25. Yancy C, Fowler M, Colluci W, Gilbert E, Lukas M, Young S. Response of black heart failure patients to carvedilol [abstract]. J Am Coll Cardiol 1997;29(Suppl A):284A.
26. Freudenberger R, Kalman J, Mannino M, Buchholz-Varley C, Ocampo O, Kukin M. Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. J Am Coll Cardiol 1997;80:1372-4.
27. The Xamoterol in Severe Heart Failure Study Group . Xamoterol in severe heart failure. Lancet 1990;336:1-6.
28. Willette R, Mitchell M, Ohlstein E, Lukas M, Ruffalo R. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart. Pharmacology 1997;56:30-6.
29. Sederberg J, Wichman S, Lindenfeld J, Wolfel E, Lowes B, Shakar S, et al. Bucindolol has no intrinsic sympathomimetic activity (ISA) in nonfailing human ventricular preparations [abstract]. J Am Coll Cardiol 2000;35:207A.
30. Gilbert E, Anderson J, Deitchman D, Yanowitz F, O'Connell J, Renlund D, et al. Long term β-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind randomized study of bucindolol versus placebo. Am J Med 1990;88:223-9.
31. Bristow M, Roden R, Lowes D, Gilbert E, Eichhorn E. The role of third generation β-blocking agents in chronic heart failure. Clin Cardiol 1998;21(Suppl I):I-3-I-13.
32. Andreka P, Aiyar N, Olson L, Wei J, Turner M, Webster K, Ohlstein E, Bishopric N. Bucindolol displays intrinsic sympoathomimetic activity in human myocardium. Circulation 2002;105:2429-34.
33. Bristow M. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
34. Lowes BD, Gilbert EM, Lindenfeld JA, Zelis R, Domanski MJ, Eichhorn EJ, et al. Differential effects of β-blocking agents on adrenergic activity. Circulation 2000;102(Suppl II):558-69.
35. Bristow M, Krause-Steinrauf H, Abraham W, Liang C-S, Hattler B, Kruger S, et al. R Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST. Circulation 2001;104(Suppl II):755.
36. Swedberg K, Bristow MR, Cohn JN, Dargie H, Wright TJ, for the MOXSE Investigators. The effects of moxonidineSR, an imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure. Circulation 2002;105:1797-803.
37. Coates AJ. Heart Failure 99-the MOXON story. Int J Cardiol 1999;71:109-11.